Stock listing
gettex:4DX Pluri Inc. Aktie
German listing (gettex) of Pluri Inc. · home listing NASDAQ:PLUR
Follow Pluri Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:PLUR
$0.94 USD +0.02 (+2.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:PLUR
- Day range
- $0.90 – $1.06 USDNov 20, 2026
- Volume
- 25,866 sharesNov 20, 2026
- Market cap
- $11.85M USDAt the close on Nov 20, 2026 · price × 12.61M shares outstanding
- 52-week range
- $0.85 – $3.99 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $43,140 USDMedian day 16,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PLUR · Home | $0.94 USD | +0.025 (+2.7%) | 25,866 | $0.975 | $1.064 | $0.90 | $0.915 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PLUR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.94 | +0.025 | +2.7% | $0.975 | $1.064 | $0.90 | 25,866 | |
| $0.915 | -0.065 | -6.6% | $0.999 | $0.999 | $0.903 | 34,973 | |
| $0.98 | -0.06 | -5.8% | $1.04 | $1.04 | $0.94 | 25,600 | |
| $1.04 | -0.01 | -1.0% | $1.05 | $1.09 | $1.01 | 23,700 | |
| $1.05 | -0.04 | -3.7% | $1.17 | $1.17 | $1.04 | 14,552 | |
| $1.09 | -0.11 | -9.2% | $1.17 | $1.19 | $1.082 | 14,893 | |
| $1.20 | +0.08 | +7.1% | $1.26 | $1.26 | $1.08 | 24,529 | |
| $1.12 | -0.06 | -5.1% | $1.19 | $1.19 | $1.088 | 16,168 | |
| $1.18 | -0.055 | -4.5% | $1.24 | $1.255 | $1.06 | 41,222 | |
| $1.235 | +0.045 | +3.8% | $1.19 | $1.235 | $1.182 | 2,707 | |
| $1.19 | -0.04 | -3.3% | $1.21 | $1.21 | $1.04 | 27,598 | |
| $1.23 | -0.04 | -3.1% | $1.27 | $1.27 | $1.202 | 16,857 | |
| $1.27 | +0.07 | +5.8% | $1.30 | $1.31 | $1.18 | 49,394 | |
| $1.20 | -0.04 | -3.2% | $1.28 | $1.30 | $1.20 | 98,937 | |
| $1.24 | +0.04 | +3.3% | $1.305 | $1.305 | $1.20 | 29,334 | |
| $1.20 | -0.03 | -2.4% | $1.255 | $1.34 | $1.18 | 37,394 | |
| $1.23 | +0.04 | +3.4% | $1.20 | $1.40 | $1.19 | 223,457 | |
| $1.19 | +0.07 | +6.2% | $1.22 | $1.29 | $1.15 | 132,774 | |
| $1.12 | +0.13 | +13.1% | $1.18 | $1.35 | $0.96 | 485,018 | |
| $0.99 | -0.02 | -2.0% | $1.06 | $1.24 | $0.97 | 70,100 | |
| $1.01 | -0.04 | -3.8% | $1.06 | $1.07 | $1.01 | 9,600 | |
| $1.05 | +0.15 | +16.7% | $1.00 | $1.08 | $0.91 | 50,100 | |
| $0.90 | +0.05 | +5.9% | $0.89 | $0.95 | $0.89 | 12,500 | |
| $0.85 | -0.08 | -8.6% | $0.90 | $0.96 | $0.85 | 8,000 | |
| $0.93 | -0.01 | -1.1% | $0.99 | $0.99 | $0.93 | 9,100 | |
| $0.94 | +0.01 | +1.1% | $0.93 | $0.96 | $0.93 | 2,000 | |
| $0.93 | -0.01 | -1.1% | $0.95 | $0.95 | $0.93 | 4,800 | |
| $0.94 | -0.03 | -3.1% | $0.96 | $0.96 | $0.91 | 14,900 | |
| $0.97 | +0.02 | +2.1% | $0.91 | $0.98 | $0.87 | 7,700 | |
| $0.95 | -0.05 | -5.0% | $0.97 | $0.97 | $0.85 | 1,500 | |
| $1.00 | -0.04 | -3.8% | $1.01 | $1.01 | $0.99 | 6,100 | |
| $1.04 | +0.05 | +5.1% | $0.98 | $1.04 | $0.85 | 61,500 | |
| $0.99 | -0.05 | -4.8% | $1.05 | $1.07 | $0.98 | 6,100 | |
| $1.04 | +0.03 | +3.0% | $1.01 | $1.06 | $1.00 | 6,000 | |
| $1.01 | -0.02 | -1.9% | $1.04 | $1.06 | $1.01 | 10,600 | |
| $1.03 | +0.03 | +3.0% | $1.00 | $1.07 | $1.00 | 10,400 | |
| $1.00 | -0.01 | -1.0% | $1.01 | $1.01 | $0.96 | 37,300 | |
| $1.01 | +0.04 | +4.1% | $0.97 | $1.04 | $0.97 | 14,600 | |
| $0.97 | -0.04 | -4.0% | $1.02 | $1.09 | $0.90 | 16,700 | |
| $1.01 | -0.04 | -3.8% | $1.13 | $1.16 | $1.01 | 5,100 | |
| $1.05 | -0.01 | -0.9% | $1.04 | $1.11 | $0.98 | 14,500 | |
| $1.06 | -0.04 | -3.6% | $1.08 | $1.08 | $1.01 | 14,800 | |
| $1.10 | +0.03 | +2.8% | $1.06 | $1.14 | $1.00 | 31,800 | |
| $1.07 | -0.01 | -0.9% | $1.08 | $1.15 | $1.01 | 8,300 | |
| $1.08 | 0.00 | 0.0% | $1.08 | $1.16 | $1.02 | 23,800 | |
| $1.08 | -0.06 | -5.3% | $1.06 | $1.14 | $1.06 | 41,600 | |
| $1.14 | -0.03 | -2.6% | $1.19 | $1.29 | $1.10 | 30,800 | |
| $1.17 | -0.07 | -5.6% | $1.26 | $1.31 | $1.14 | 12,900 | |
| $1.24 | +0.06 | +5.1% | $1.19 | $1.36 | $1.19 | 7,000 | |
| $1.18 | -0.07 | -5.6% | $1.23 | $1.31 | $1.18 | 9,600 | |
| $1.25 | -0.12 | -8.8% | $1.34 | $1.34 | $1.24 | 25,400 | |
| $1.37 | +0.10 | +7.9% | $1.26 | $1.39 | $1.25 | 7,400 | |
| $1.27 | -0.09 | -6.6% | $1.36 | $1.40 | $1.27 | 17,600 | |
| $1.36 | -0.01 | -0.7% | $1.41 | $1.45 | $1.31 | 15,500 | |
| $1.37 | -0.05 | -3.5% | $1.44 | $1.45 | $1.25 | 13,600 | |
| $1.42 | -0.04 | -2.7% | $1.51 | $1.52 | $1.38 | 37,700 | |
| $1.46 | -0.01 | -0.7% | $1.44 | $1.46 | $1.44 | 3,700 | |
| $1.47 | -0.06 | -3.9% | $1.53 | $1.57 | $1.41 | 48,900 | |
| $1.53 | 0.00 | 0.0% | $1.52 | $1.63 | $1.46 | 24,300 | |
| $1.53 | +0.05 | +3.4% | $1.51 | $1.64 | $1.45 | 100,500 | |
| $1.48 | -0.18 | -10.8% | $1.63 | $1.63 | $1.48 | 96,500 | |
| $1.66 | +0.10 | +6.4% | $1.57 | $1.67 | $1.57 | 19,000 | |
| $1.56 | -0.15 | -8.8% | $1.68 | $1.71 | $1.55 | 38,200 | |
| $1.71 | -0.06 | -3.4% | $1.70 | $1.84 | $1.70 | 4,600 | |
| $1.77 | +0.01 | +0.6% | $1.75 | $1.77 | $1.72 | 15,200 |
Splits
3 splits since 2007 · NASDAQ:PLUR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-8 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-200 | Consolidation |
- Ticker
- gettex:4DX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
Pluri CEO Letter: Turning Our Cell Technology and Experience into Commercial Opportunity
Latest deck · Oct 29, 2026
Corporate Update (October 2026)
Corporate update · 24 slides
Latest news
Pluri CEO Letter: Turning Our Cell Technology and Experience into Commercial Opportunity
Nov 16, 2026
Closed $1.04 (-1.0%) on Nov 16, 2026
Pluri Adds ISO 9001 and ISO 13485 Certifications to Support PluriCDMO Commercial Expansion
Nov 9, 2026
Closed $1.18 (-4.5%) on Nov 9, 2026
Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments
Oct 27, 2026
Closed $1.19 (+6.2%) on Oct 27, 2026
Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform
Oct 26, 2026
Closed $1.12 (+13.1%) on Oct 26, 2026
Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine
Oct 26, 2026
Closed $1.12 (+13.1%) on Oct 26, 2026
Pluri Chairman and Active Investor Alejandro Weinstein to Acquire EIB Loan, in Strong Vote of Confidence in the Company
Oct 21, 2026
Closed $1.05 (+16.7%) on Oct 21, 2026
Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor
Aug 27, 2026
Closed $1.53 (+3.4%) on Aug 27, 2026
Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment
Aug 17, 2026
Closed $1.60 (0.0%) on Aug 17, 2026
Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK
Jul 28, 2026
Closed $1.68 (+2.4%) on Jul 28, 2026
Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
Jul 14, 2026
Closed $1.68 (+3.1%) on Jul 14, 2026
Pluri Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 51 in all · newest Nov 16, 2026 · oldest 2019
- Decks
- 21 decks · latest Oct 29, 2026
Where Pluri Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PLUR · Home listing | NASDAQ | United States | USD |
| TASE:PLUR | TASE | Israel | ILA |
| gettex:4DX · This page | gettex | Germany | EUR |
| Frankfurt:4DX | Frankfurt | Germany | EUR |
| BOATS:PLUR | BOATS | United States | USD |
| Lang & Schwarz:A408KW | Lang & Schwarz | Germany | EUR |
| Munich:4DX | Munich | Germany | EUR |
Valuation
EV/sales 26.5× against a median of 4.8×: 4th lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $38.65M USD
- P/E
- Loss
- EV/sales
- 26.5×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 51.9%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.53
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Pluri Inc. · NASDAQ:PLUR | US$11.85M | US$38.65M | n/a | 26.5× | n/a | n/a | n/a | n/a | 0.53 |
| MIRA Pharmaceuticals, Inc. · NASDAQ:MIRA | US$12.23M | US$5.26M | n/a | n/a | n/a | 1.8× | n/a | 0.0× | 1.48 |
| Genflow Biosciences PLC · LSE:GENF | US$12.06M | US$11.23M | n/a | n/a | n/a | 48.5× | n/a | 0.0× | n/a |
| Xintela AB · OMXSTO:XINT | US$11.89M | US$11.82M | n/a | 39.8× | n/a | n/a | n/a | n/a | n/a |
| BioCardia, Inc. · NASDAQ:BCDA | US$11.88M | US$10.22M | n/a | n/a | n/a | 14.2× | n/a | 0.7× | 0.42 |
| Synlogic Inc · OTC:SYBX | US$11.76M | US$201,442 | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 0.50 |
| Imugene Ltd · ASX:IMU | US$11.74M | US$14.16M | n/a | n/a | n/a | 2.0× | n/a | 0.7× | n/a |
| Radiopharm Theranostics Limited · ASX:RAD | US$11.59M | US$8.85M | n/a | 4.8× | n/a | 0.7× | n/a | 0.0× | n/a |
| Simris Group AB Class B · OMXSTO:SIMRIS_B | US$11.55M | US$19.55M | n/a | 144× | n/a | 154× | n/a | 117× | n/a |
| Aelis Farma SA · EURONEXT:AELIS | US$11.55M | US$9.09M | n/a | 4.0× | n/a | 4.5× | −308.7% | 1.9× | n/a |
| Dyadic International, Inc. · NASDAQ:DYAI | US$11.51M | US$12.03M | n/a | 3.9× | n/a | n/a | −226.9% | n/a | 1.12 |
| Median of the others | US$11.75M | US$10.73M | 4.8× | 3.3× | −267.8% | 0.3× | 0.81 |
Forecasts
Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 12.00 USD · Analysts' mean
- EPS, year to Jun 2026
- -2.70 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Katty Dowery | CEO of CellaV Health & Aesthetics |
| Yaky Yanay | CEO & President |
| Liat Zalts | Chief Financial Officer |
| Nofar Glaich-Dabach | VP Human Resources |
| Ori Shalem | VP Operations and Manufacturing |
| Efrat Kaduri | Chief Business Development Officer – Pharma |
| Lior Raviv | Chief Technology Officer |
| Nimrod Bar Zvi | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| Alejandro Weinstein | Chairman of the Board, Board Member |
| Doron Shorrer | Board Member |
| Maital Shemesh-Rasmussen | Board Member |
| Rami Levi | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2027 | Nov 12, 2026 | −12.5% |
| Q4 2026 | Sep 16, 2026 | −7.7% |
| Q1 2026 | Nov 12, 2025 · After close | −6.1% |
| Q4 2025 | Sep 17, 2025 · After close | −4.3% |
| Q3 2025 | May 7, 2025 · After close | +6.9% |
| Q2 2025 | Feb 10, 2025 · After close | +0.7% |
| Q1 2025 | Nov 11, 2024 · After close | +8.4% |
| Q4 2024 | Sep 10, 2024 · After close | −0.8% |
| Q3 2024 | May 9, 2024 · After close | −2.4% |
| Q2 2024 | Feb 12, 2024 · After close | −7.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Nov 13, 2023 · After close | −1.8% |
| Q4 2023 | Sep 12, 2023 · After close | −1.6% |
| Q3 2023 | May 9, 2023 · After close | 0.0% |
| Q2 2023 | Feb 13, 2023 · After close | −1.6% |
| Q1 2023 | Nov 10, 2022 · After close | +9.7% |
| Q4 2022 | Sep 21, 2022 · After close | +1.3% |
| Q3 2022 | May 9, 2022 · After close | +3.7% |
| Q2 2022 | Feb 7, 2022 · After close | +1.1% |
| Quarter to Sep 30, 2021 | Nov 8, 2021 · After close | +9.2% |
| Quarter to Jun 30, 2021 | Sep 13, 2021 · After close | −2.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (October 2026) | Corporate update | 24 slides | Oct 29, 2026 |
| Investor Presentation (October 2026) | Investor deck | 18 slides | October 2026 |
| Investor Presentation (April 2026) | Investor deck | 20 slides | April 2026 |
| Investor Presentation (March 2026) | Investor deck | 22 slides | March 2026 |
| Investor Presentation (January 2026) | Investor deck | 27 slides | January 2026 |
| Investor Presentation (November 2025) | Investor deck | 25 slides | November 2025 |
| Investor Presentation (September 2025) | Investor deck | 26 slides | September 2025 |
| Investor Presentation (July 2025) | Investor deck | 25 slides | July 2025 |
| Investor Presentation (May 2025) | Investor deck | 25 slides | May 2025 |
| Investor Presentation (April 2025) | Investor deck | 26 slides | Apr 1, 2025 |
All 21 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (April 2025) | Investor deck | 25 slides | April 2025 |
| Investor Presentation (April 2025) | Investor deck | 24 slides | April 2025 |
| Investor Presentation (March 2025) | Investor deck | 26 slides | March 2025 |
| Investor Presentation (February 2025) | Investor deck | 26 slides | February 2025 |
| Investor Presentation (December 2024) | Investor deck | 29 slides | December 2024 |
| Investor Presentation (September 2024) | Investor deck | 29 slides | September 2024 |
| Investor Presentation (May 2024) | Investor deck | 35 slides | May 2024 |
| Pluristem Therapeutics — Corporate Update (May 2021) | Corporate update | 20 slides | May 3, 2021 |
| Pluristem Therapeutics — Corporate Update (December 2020) | Corporate update | 15 slides | Dec 9, 2020 |
| Pluristem Therapeutics — IPO Roadshow (October 2017) | IPO roadshow | 43 slides | Oct 30, 2017 |
| Pluristem Therapeutics — Investor Presentation (May 2015) | Investor deck | 44 slides | May 27, 2015 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common shares (or common share equivalents) with concurrent private placement of warrants Announced: about US$3.3M · US$1.5 a share · ½ warrant at US$1.65 for 66 months · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners (lead) Use of proceeds: Working capital and other general corporate purposes | Aug 27, 2026 |
| Private placement of common shares and warrants Announced: about US$2.5M · US$4 a share · Warrants at US$4.25 Buyers: entity beneficially owned by Mr. Weinstein (625,000 common shares and warrants for up to 625,000 additional shares) Insiders: The investor is an entity beneficially owned by Alejandro Weinstein, newly appointed Chairman and one of the largest shareholders Use of proceeds: General working capital | Dec 9, 2025 |
| Private placement of common shares and warrants Announced: US$3.5M · US$4.61 a share · Warrants at US$5.568 Buyers: Merchant Adventure Fund, L.P. ($3.5 million; 759,219 common shares and warrants to purchase up to 45,553 common shares) Use of proceeds: Support the company's growth in cell-based technology and expansion across pharma, foodtech and agtech | Feb 4, 2025 |
| Strategic investment of common shares, common warrants and pre-funded warrants Announced: US$6.5M · US$4.61 a share · Warrants at US$5.568 for 36 months Buyers: Alejandro Weinstein (Leads the $6.5 million investment through a wholly-owned company; will join the Board of Directors) Use of proceeds: Working capital and general corporate purposes | Jan 23, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.02M | 1.34M | 326.0K | 287.0K | 234.0K | 0 | 23.0K | 54.0K | 50.0K | |
| Cost of revenue | 563.0K | 682.0K | 4.00K | 9.00K | 1.05M | 1.37M | 1.57M | 2.00K | 2.00K | 2.18M |
| Gross profit | 453.0K | 654.0K | 322.0K | 278.0K | 234.0K | -1.37M | 23.0K | 52.0K | 48.0K | -2.18M |
| Research and development | 15.1M | 12.9M | 12.4M | 15.7M | 24.6M | 30.5M | 23.1M | 29.9M | 26.4M | 24.0M |
| Selling, general and administrative | 10.3M | 9.98M | 10.0M | 11.8M | 17.4M | 20.6M | 7.92M | 9.16M | 11.2M | 6.93M |
| Operating income | -24.9M | -22.2M | -22.2M | -27.2M | -41.6M | -50.6M | -29.5M | -35.5M | -33.7M | -28.0M |
| Depreciation and amortization | 511.0K | 316.0K | 253.0K | 362.0K | 1.05M | 1.37M | 1.57M | 1.96M | 2.02M | 2.18M |
| EBITDA | -24.4M | -21.9M | -21.9M | -26.9M | -40.5M | -49.3M | -27.9M | -33.6M | -31.7M | -25.8M |
| Interest expense | 932.0K | 873.0K | 866.0K | 843.0K | 887.0K | 78.0K | 196.0K | 29.0K | 937.0K | |
| Income before tax | -25.4M | -23.3M | -21.3M | -28.9M | -41.4M | -49.9M | -29.2M | -35.3M | -26.1M | -27.8M |
| Income tax | -25.0K | -5.00K | 410.0K | 277.0K | -351.0K | 78.0K | 196.0K | -94.0K | 7.61M | -205.0K |
| Net income | -23.8M | -22.6M | -20.9M | -28.3M | -41.2M | -49.9M | -29.2M | -35.3M | -26.1M | -27.8M |
| Earnings per share, basic | -2.44 | -3.56 | -3.99 | -6.24 | -1.28 | -1.77 | -1.60 | -2.90 | -2.50 | -3.20 |
| Earnings per share, diluted | -2.44 | -3.56 | -3.99 | -6.24 | -1.28 | -1.77 | -1.60 | -2.90 | -2.50 | -3.20 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.53M | 5.89M | 6.78M | 5.36M | 9.77M | 31.2M | 8.27M | 4.11M | 8.82M | 4.71M |
| Short-term investments | 4.28M | 14.7M | 23.2M | 34.8M | 45.2M | 33.7M | 37.5M | 19.6M | 21.1M | 6.24M |
| Receivables | 219.0K | 722.0K | 638.0K | 527.0K | 3.00K | 19.0K | 1.61M | 1.42M | 58.0K | 1.04M |
| Inventory | 222.0K | 269.0K | 597.0K | 555.0K | 692.0K | |||||
| Current assets | 8.73M | 22.1M | 31.1M | 41.4M | 57.7M | 67.4M | 48.5M | 26.4M | 32.0M | 29.0M |
| Property, plant and equipment | 1.57M | 1.82M | 688.0K | 688.0K | 739.0K | 1.50M | 2.52M | 3.84M | 5.68M | 7.28M |
| Goodwill | 3.14M | 3.14M | 0 | |||||||
| Total assets | 24.9M | 38.7M | 39.5M | 50.8M | 68.1M | 93.5M | 65.5M | 31.3M | 39.0M | 37.5M |
| Accounts payable | 702.0K | 866.0K | 964.0K | 1.81M | 1.78M | 2.53M | 1.97M | 2.28M | 3.26M | 1.97M |
| Current liabilities | 32.7M | 32.3M | 4.45M | 5.62M | 6.83M | 11.5M | 7.99M | 8.16M | 8.55M | 5.41M |
| Long-term debt | 24.0M | 23.5M | 21.7M | 23.9M | 1.26M | |||||
| Total debt | 34.9M | 34.0M | 29.6M | 29.9M | 28.8M | 24.6M | 1.58M | |||
| Total liabilities | 42.3M | 39.5M | 34.1M | 35.5M | 35.9M | 36.4M | 9.43M | 9.49M | 10.5M | 7.28M |
| Shareholders' equity | -23.0M | -6.84M | 96.0K | 13.4M | 30.0M | 57.2M | 56.1M | 21.8M | 28.5M | 30.3M |
| Shares outstanding | 10.8M | 7.89M | 5.41M | 5.16M | 32.5M | 32.0M | 25.5M | 15.1M | 11.4M | 96.9M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -19.6M | -18.2M | -18.0M | -22.9M | -36.5M | -30.9M | -26.4M | -29.5M | -21.4M | -21.6M |
| Capital spending | -633.0K | -1.62M | -323.0K | -262.0K | -280.0K | -373.0K | -270.0K | -239.0K | -342.0K | -378.0K |
| Free cash flow | -20.2M | -19.8M | -18.3M | -23.1M | -36.8M | -31.3M | -26.6M | -29.7M | -21.7M | -22.0M |
| Cash from investing | 9.90M | 8.03M | 10.6M | 9.70M | 11.8M | -7.26M | -30.5M | 1.17M | 5.68M | 4.36M |
| Cash from financing | 7.04M | 9.53M | 8.84M | 8.02M | 7.50M | 61.4M | 60.9M | 23.6M | 19.9M | 15.8M |
| Change in cash | -2.62M | -475.0K | 1.42M | -5.16M | -20.4M | 22.6M | 4.04M | -4.70M | 4.11M | -1.52M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| S-3/A · Registration statement, amended | Nov 12, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2026 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 20, 2026 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Oct 16, 2026 | Other filings | SEC |
| S-1 · Registration statement | Oct 6, 2026 | Offer document | SEC |
| S-3 · Registration statement | Sep 10, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-8 · Registration statement for employee plans | Sep 10, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Sep 10, 2026 | Offer document | SEC |
| 10-K · Annual report | Sep 10, 2026 | Annual report | SEC |
| D | Sep 4, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Aug 28, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 28, 2026 | Material contract | SEC |
| 424B3 · Prospectus | Aug 26, 2026 | Offer document | SEC |
| 4 · Change in ownership | Aug 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 17, 2026 | Current report | SEC |
| 8-K · Current report | Jul 14, 2026 | Current report | SEC |
| 8-K · Current report | Jul 13, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 1, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 22, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 1, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 23, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 27, 2026 | Material contract | SEC |
| 8-K · Current report | Mar 2, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Feb 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jan 22, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 9, 2025 | Material contract | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 16, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 14, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Sep 26, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 23, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | Sep 22, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Sep 22, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 17, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Sep 17, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Sep 17, 2025 | Offer document | SEC |
| 10-K · Annual report | Sep 17, 2025 | Annual report | SEC |
| 8-K · Current report | Sep 12, 2025 | Current report | SEC |
| 8-K · Current report | Sep 11, 2025 | Management or board change | SEC |
| 8-K · Current report | Jul 3, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 9, 2025 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | May 28, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | May 27, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | May 27, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 27, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | May 21, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 20, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 8, 2025 | Current report | SEC |
| 8-K · Current report | Apr 29, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 28, 2025 | Current report | SEC |
| 8-K · Current report | Apr 25, 2025 | Material contract | SEC |
| 8-K · Current report | Apr 17, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 16, 2025 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Apr 15, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 3, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 1, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 27, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 26, 2025 | Other filings | SEC |
| D | Mar 19, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 19, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Mar 14, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 13, 2025 | Material contract | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 18, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Feb 6, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 4, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 29, 2025 | Material contract | SEC |
| 8-K · Current report | Jan 21, 2025 | Current report | SEC |
| 8-K · Current report | Nov 27, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 1, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 10-K · Annual report | Sep 18, 2024 | Annual report | SEC |
| 8-K · Current report | Jul 23, 2024 | Current report | SEC |
| 8-K · Current report | Jul 8, 2024 | Current report | SEC |
| 8-K · Current report | Jul 2, 2024 | Management or board change | SEC |
| 8-K · Current report | Jun 26, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 18, 2024 | Material contract | SEC |
| 8-K · Current report | May 31, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | May 9, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | May 9, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| ARS · Annual report to shareholders | May 1, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | May 1, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 17, 2024 | Current report | SEC |
| 8-K · Current report | Apr 1, 2024 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Feb 13, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 13, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Feb 12, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 1, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 26, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 24, 2024 | Current report | SEC |
| 8-K · Current report | Jan 8, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 19, 2023 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 22, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 19, 2023 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Sep 15, 2023 | Big-stake notice | SEC |
| S-3/A · Registration statement, amended | Sep 12, 2023 | Offer document | SEC |
| 10-K · Annual report | Sep 12, 2023 | Annual report | SEC |
| UPLOAD · Letter from the SEC | Jul 25, 2023 | Other filings | SEC |
| S-3 · Registration statement | Jul 20, 2023 | Offer document | SEC |
| 4 · Change in ownership | Jul 13, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 13, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 13, 2023 | Management or board change | SEC |
| 8-K · Current report | Jul 11, 2023 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jun 9, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 6, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 5, 2023 | Other filings | SEC |
| S-3 · Registration statement | Jun 1, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | May 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Apr 27, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Apr 25, 2023 | Current report | SEC |
| ARS · Annual report to shareholders | Feb 27, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Feb 27, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Feb 16, 2023 | Meeting notice | SEC |
| SC 13G · Big-stake notice | Feb 16, 2023 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Feb 14, 2023 | Current report | SEC |
| S-8 · Registration statement for employee plans | Feb 13, 2023 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 13, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Feb 13, 2023 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Feb 6, 2023 | Current report | SEC |
| 8-K · Current report | Jan 24, 2023 | Current report | SEC |
| SC 13D · Big-stake notice | Jan 4, 2023 | Big-stake notice | SEC |
| D | Dec 30, 2022 | Other filings | SEC |
| 8-K · Current report | Dec 28, 2022 | Current report | SEC |
| 4 · Change in ownership | Dec 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2022 | Insider trade | SEC |
| 8-K · Current report | Dec 19, 2022 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 10, 2022 | Quarterly report | SEC |
| 8-K · Current report | Oct 13, 2022 | Current report | SEC |
| 8-K · Current report | Sep 29, 2022 | Current report | SEC |
| 424B5 · Prospectus | Sep 21, 2022 | Offer document | SEC |
| 10-K · Annual report | Sep 21, 2022 | Annual report | SEC |
| 8-K · Current report | Jul 25, 2022 | Current report | SEC |
| 8-K · Current report | Jul 13, 2022 | Current report | SEC |
| 8-K · Current report | Jun 23, 2022 | Management or board change | SEC |
| 10-Q · Quarterly report | May 9, 2022 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Apr 27, 2022 | Meeting notice | SEC |
| 8-K · Current report | Mar 24, 2022 | Current report | SEC |
| 8-K · Current report | Mar 8, 2022 | Current report | SEC |
| 8-K · Current report | Feb 28, 2022 | Current report | SEC |
| 4 · Change in ownership | Feb 14, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Feb 7, 2022 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Jan 26, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Jan 10, 2022 | Material contract | SEC |
| 8-K · Current report | Jan 3, 2022 | Current report | SEC |
| 8-K · Current report | Dec 27, 2021 | Current report | SEC |
| 8-K · Current report | Nov 16, 2021 | Current report | SEC |
| 10-Q · Quarterly report | Nov 8, 2021 | Quarterly report | SEC |
| 10-K · Annual report | Sep 13, 2021 | Annual report | SEC |
This page holds 200 of 956 filings. Open Filings
Cap table
Built by 6ix from Pluri Inc.’s releases · as of Aug 27, 2026
- Common shares
- 12,611,335
- Fully diluted
- 12,611,335
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 12,611,335 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 12,611,335 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Chen Franco-Yehuda Other companies: DarioHealth Corp. (Chief Financial Officer · Since at least May 15, 2025) | Chief Financial Officer · Sep 10, 2020 – Sep 18, 2024 · Past |
| Mark Germain Other companies: Scinai Immunotherapeutics Ltd. (Director · Since at least Jan 1, 2023) | Director · Dec 14, 2017 – Sep 10, 2020 · Past |
| Varda Shalev Other companies: Teva Pharmaceutical Industries Limited (Director · Since at least Sep 1, 2023) | Director · Jul 15, 2021 – Jul 15, 2021 · Past |
| Alejandro Weinstein | Chairman of the Board, Board Member · Since at least Oct 27, 2026 |
| Alexandre Weinstein Manieu | Director · Since at least Feb 25, 2025 |
| Boaz Gur-Lavie | Chief Financial Officer · Feb 4, 2014 – Jan 8, 2015 · Past |
| Doron Shorrer | Board Member · Since at least Jan 17, 2006 |
| Efrat Kaduri | Chief Business Development Officer – Pharma · Since at least Nov 5, 2026 |
| Eitan Ajchenbaum | Director · Since at least Sep 10, 2025 |
| Erez Egozi | Chief Financial Officer · Mar 29, 2017 – Dec 19, 2018 · Past |
All 28 people
| Person | Seat |
|---|---|
| Hava Meretzki | Director · Jan 17, 2006 – Dec 19, 2018 · Past |
| Isaac Braun | Director · Jan 17, 2006 – Sep 10, 2020 · Past |
| Israel Ben-Yoram | Director · Dec 26, 2007 – Apr 8, 2019 · Past |
| Katty Dowery | CEO of CellaV Health & Aesthetics · Since at least Jul 28, 2026 |
| Liat Zalts | Chief Financial Officer · Since at least Sep 30, 2024 |
| Lior Raviv | Chief Technology Officer · Since at least Nov 5, 2026 |
| Lorne Kenneth Abony | Director · Jan 23, 2024 – Jan 23, 2024 · Past |
| Maital Shemesh-Rasmussen | Board Member · Since at least Jan 5, 2021 |
| Nachum Rosman | Director · Oct 9, 2007 – Dec 19, 2018 · Past |
| Nimrod Bar Zvi | Chief Commercial Officer · Since at least Nov 4, 2026 |
| Nofar Glaich-Dabach | VP Human Resources · Since at least Nov 5, 2026 |
| Ori Shalem | VP Operations and Manufacturing · Since at least Nov 5, 2026 |
| Pinhas Doron Birger | Director · Jul 15, 2021 – Feb 25, 2025 · Past |
| Rami Levi | Board Member · Since at least Jan 5, 2021 |
| Shai Pines | Director · Dec 8, 2008 – Dec 21, 2011 · Past |
| Yaky Yanay | CEO & President · Since at least Nov 1, 2006 |
| Yossi Keret | Chief Financial Officer · Jan 17, 2006 – Jan 17, 2006 · Past |
| Zami Aberman | Director · Since at least Feb 10, 2022 |
Log in to ask 6ix AI your own questions about Pluri Inc.